ReviewThe Medical clinics of North America2023
Atherosclerotic Disease: Pathogenesis and Approaches to Management.
Review in The Medical clinics of North America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- LDL-Cholesterol-Lowering Effects of a Dietary Supplement Containing Onion and Garlic Extract Used in Healthy Volunteers.Nutrients · 2024Trial
- Lipid-lowering medication reduces more target lesion than non-target lesion revascularizations: a cohort study.Annals of medicine · 2026Article
- Follistatin Mitigates Atherosclerosis Through Activation of Arginine Metabolism and Adipose Browning.Cells · 2026Article
- Clinical observation of renal artery stenosis treated with PCSK9 inhibitor.BMC cardiovascular disorders · 2026Observational
- LncRNA H19 drives atherosclerosis progression via the miR-let-7a/ITGB3 axis.Frontiers in physiology · 2026Article
- Predictors and impact for side branch occlusion after bioresorbable vascular scaffold implantation: insights from multimodal imaging and 2-year clinical outcomes.BMC cardiovascular disorders · 2025Article
- Epigenetic‑ncRNA crosstalk in atherosclerosis: Mechanisms, disease progression and therapeutic potential (Review).International journal of molecular medicine · 2025Review
- Assessing the therapeutic potential of a panel of novel VCAM-1 antibodies using microfluidic and three-dimensionalAntibody therapeutics · 2025Article
- Risk Factor Assessments and Lipid Management Patterns in Hospitalised Patients in Malaysia: The Atherosclerotic Cardiovascular Disease Study.The Malaysian journal of medical sciences : MJMS · 2025Article
- Association between persistent nocturnal sleep duration patterns and carotid intima-media thickness in Chinese patients with type 2 diabetes.Scientific reports · 2025Article
- The Prevalence of Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes in Jordan: The PACT-MEA Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Impact of Carotid Artery Geometry and Clinical Risk Factors on Carotid Atherosclerotic Plaque Prevalence.Journal of personalized medicine · 2025Article
- WTAP Promotes Atherosclerosis by Inducing Macrophage Pyroptosis and M1 Polarization through Upregulating NLRP3.Applied biochemistry and biotechnology · 2025Article
- Review
- Trends in atherosclerotic heart disease-related mortality among U.S. adults aged 35 and older: A 22-year analysis.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Antioxidant and Anti-Inflammatory Effects of Bioactive Compounds in Atherosclerosis.International journal of molecular sciences · 2025Review
- Overexpression of Neural Precursor Cell Expressed Developmentally Downregulated 9 (NEDD9) reduces ox-LDL-induced Anoikis in atherosclerotic vascular endothelial cells.International journal of cardiology. Heart & vasculature · 2025Article
- Review
- Strategies to Improve Health Care Provider Prescription of and Patient Adherence to Guideline-Recommended Cardiovascular Medications for Atherosclerotic Occlusive Disease: Protocol for Two Systematic Reviews and Meta-Analyses of Randomized Controlled Trials.JMIR research protocols · 2025Article
- Combination of Polydatin and Hawthorn Leave Flavonoids Ameliorate Atherosclerotic Plaque Vulnerability in ApoEJournal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Atherosclerotic disease, including stroke and myocardial infarction, is the leading cause of morbidity and mortality worldwide. Atherosclerotic plaque formation occurs in the setting of excess oxidative and hemodynamic stress and is perpetuated by smoking, poor diet, dyslipidemia, hypertension, and diabetes. Plaque may rupture, resulting in acute thrombotic events. Smoking cessation, lifestyle modification, risk factor optimization, and antithrombotic therapies are the mainstays of atherosclerotic disease management and are the cornerstones to reduce morbidity and mortality in this high-risk patient population. Novel therapeutics are in development and will add to the growing armamentarium available to physicians who manage atherosclerotic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.